Hanmi Pharmaceutical Group has embarked on a major organizational restructuring to regain its reputation as a prominent drug development company. The plan involves establishing the Planning and Strategy Division and the Innovation Division at Hanmi Science, the holding company, to respond swiftly to changes in the global healthcare industry.
Hanmi Group announced on the 2nd that it carried out an organizational restructuring to establish and operate medium- to long-term business strategies. The focus is on strengthening organic connections between the holding company and operating companies, and laying out a strategic framework to create future growth drivers.
The newly established Planning and Strategy Division at Hanmi Science is composed of the Management Strategy Team and the Business Strategy Team. The Management Strategy Team is responsible for establishing the medium- to long-term strategies for the group and its affiliates and promoting new growth business planning. The Business Strategy Team will execute various strategic investments.
The Innovation Division is composed of the 'Connect & Develop' Strategy Team, the 'Launching & Development' Strategy Team, and the IP (Intellectual Property) Team. It will oversee Hanmi Group's open innovation and strategies relating to technology transfer and licensing.
On this day, Kim Jae-kyo, CEO of Hanmi Science, delivered his first CEO message to the employees after his appointment. He said, "When the synergies among the group companies converge, it will enhance Hanmi Group's future value and lead to an increase in shareholder value," adding, "As a prominent drug development company, let’s leap forward as a global pharmaceutical company by carrying on the founders' wish.”
CEO Kim stated, "As a holding company, Hanmi Science, as a core operating company, Hanmi Pharmaceutical, and as over 30 affiliates, must further solidify Hanmi's identity as a 'prominent drug development company' through organic cooperation. When such synergies among the group companies converge, it will enhance Hanmi Group's future value and lead to an increase in shareholder value."